The Phase III data of Bharat Biotech's Covaxin is finally out and the results are quite promising. The vaccine has demonstrated that it is 77.8 per cent effective against symptomatic COVID-19, through evaluation of 130 confirmed cases, with 24 observed in the vaccine group versus 106 in the placebo group.
The efficacy data which was peer reviewed also said the vaccine demonstrated 63.6 per cent protection against asymptomatic COVID-19 and 65.2 per cent safety against the Delta variant besides showing 70.8 per cent guard against all variants of SARS-CoV-2 virus. The efficacy analysis demonstrated that Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19. "The peer-review of Covaxin phase III clinical trial data in The Lancet, an authoritative voice in global medicine validates our commitment to data transparency and meeting the stringent peer-review standards of world leading medical journals."
"The data from our product development and clinical trials have been published in 10 peer-reviewed journals, making Covaxin one of the most highly published COVID-19 vaccines in the world. This accomplishment reflects the undeterred commitment by my team members at Bharat Biotech, our public partners, Indian Council of Medical Research, National Institute of Virology, and the trust imposed by our trial participants who made this happen," Bharat Biotech Chairman Krishna Ella said in a statement. The phase 3 trial Efficacy and Safety Study involving 25,800 volunteers across 25 sites in India is India's largest ever clinical trial conducted for a COVID-19 vaccine.Balram Bhargava, Director General, Indian Council of Medical Research (ICMR) said, following successful isolation of the SARS-CoV-2 virus at NIV, ICMR and Bharat Biotech embarked upon one of the most successful public-private partnerships to develop the virus isolate into an effective COVID-19 vaccine.
READ ALSO : Study finds that majority of Indians experience mild or no side effects post COVID-19 vax
"I am delighted to see that the phase III efficacy data has also been published in The Lancet, one of the most reputed journals worldwide. This itself speaks high about the strong position of Covaxin amongst other global front-runners COVID-19 vaccines," Bhargava said. The bench to bedside journey of Covaxin in less than 10 months showcases the immense strength of "Atmanirbhar Bharat" along with the Indian academia and industry in fighting against the odds and carving a niche in the global community, he added.
Recently, the World Health Organisation granted emergency use listing to Covaxin, enabling countries to expedite their regulatory approval to import and administer doses.
